Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Zealand Opens Access to Clopidogrel, Leaving Out Sanofi's Plavix

This article was originally published in PharmAsia News

Executive Summary

TOKYO - New Zealand's Pharmaceutical Management Agency announced open access for cardiovascular drug clopidogrel, dropping patient price significantly, essentially removing Sanofi-Aventis' Plavix from the country's market
Advertisement

Related Content

Pfizer, Sanofi-Aventis, Eli Lilly: Emerging Markets Earnings Roundup (Part 3 of 3)
New Zealand's PHARMAC Widens Access To Atorvastatin By Awarding Sole Supply Status For Generic
Sole-supplier Contracts Help New Zealand Save Money For Innovative Drugs
Sole-supplier Contracts Help New Zealand Save Money For Innovative Drugs
Advertisement
UsernamePublicRestriction

Register

SC075742

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel